EW Stock Recent News

Vancouver, British Columbia--(Newsfile Corp. - July 2, 2025) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that the Board of directors has approved, subject to shareholder approval, distribution of capital to the shareholders. The distribution is intended to be structured as a return of capital to the Company's shareholders as of a record date to be determined in the near future.

Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.

EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.

PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.

Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy.

EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible lat.

Edwards Lifesciences‘ EW shares are trading higher Thursday after the company reported first-quarter 2025 sales of $1.41 billion.

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.

Edwards Lifesciences Corporation (NYSE:EW ) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Company Participants Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader, TMTT Larry Wood - Global Group President, TAVR and Surgical Conference Call Participants Larry Biegelsen - Wells Fargo David Roman - Goldman Sachs Travis Steed - Bank of America Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Matt Taylor - Jefferies Joanne Wuensch - Citibank Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Patrick Wood - Morgan Stanley Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2025 Results. [Operator Instructions] As a reminder, this conference is being recorded.